Hong Kong stock anomaly: Tongyuan Kang Medicine-B (02410.HK) surged by over 40%. The key registration II phase clinical results of Aedoitinib recently appeared in the WCLC oral report.

According to the Securities Times APP, Tongyuan Kang Pharmaceutical-B (02410.HK) surged more than 40% in the morning trading session. As of the time of publication, it has increased by 37.9% to 21.36 Hong Kong dollars, with a turnover of 1.664 billion Hong Kong dollars.